Plain-English translation of NCT06089577 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
During a coronary artery procedure (called PCI), doctors sometimes damage tiny blood vessels in the heart, which can cause chest pain even after the procedure is successful. This trial is testing whether cangrelor, a fast-acting blood thinner given through an IV, can prevent this damage better than the standard approach. The medication starts working within minutes, unlike oral blood thinners that take longer to become effective.
Most patients undergoing these heart procedures don't receive adequate blood-thinning treatment beforehand, leaving them at higher risk for complications. This medication works much faster than standard treatments, which could potentially protect your small heart blood vessels and reduce chest pain after the procedure.
You likely qualify if…
You likely don't qualify if…
If you are in the treatment group, you will receive cangrelor through an IV starting before your scheduled PCI procedure—a loading dose followed by a 2-hour infusion. You will then receive standard oral blood thinners (clopidogrel and aspirin) as usual. The control group receives only the standard oral blood thinners before or after the procedure. The trial involves 80 participants total, and your participation would include the procedure itself and follow-up care to monitor how well your small heart blood vessels are protected.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Italy